NL8100510A - 1-AMINOADAMANTS D, L-2-ACETAMIDO-3-PHENYL PROPIONATE. - Google Patents
1-AMINOADAMANTS D, L-2-ACETAMIDO-3-PHENYL PROPIONATE. Download PDFInfo
- Publication number
- NL8100510A NL8100510A NL8100510A NL8100510A NL8100510A NL 8100510 A NL8100510 A NL 8100510A NL 8100510 A NL8100510 A NL 8100510A NL 8100510 A NL8100510 A NL 8100510A NL 8100510 A NL8100510 A NL 8100510A
- Authority
- NL
- Netherlands
- Prior art keywords
- acetamido
- dose
- aminoadamantane
- compound
- rats
- Prior art date
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 7
- CBQJSKKFNMDLON-UHFFFAOYSA-N N-acetylphenylalanine Chemical compound CC(=O)NC(C(O)=O)CC1=CC=CC=C1 CBQJSKKFNMDLON-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 230000001430 anti-depressive effect Effects 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 238000011160 research Methods 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 238000007912 intraperitoneal administration Methods 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000008485 antagonism Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 5
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 5
- 229960003805 amantadine Drugs 0.000 description 5
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 5
- 229960003147 reserpine Drugs 0.000 description 5
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010022714 Intestinal ulcer Diseases 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000029808 Psychomotor disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C1/00—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Ι-Αττη r>oaf»flTna.ritaaxL D ,L-2-aceetamido-3-fenylpropionaat.Ι-Αττη r> oaf »flTna.ritaaxL D, L-2-acetamido-3-phenylpropionate.
VO 1566VO 1566
De uitvinding heeft betrekking op een nieuwe verbinding met anti-depressieve werkzaamheid, namelijk 1-aminoadamantaan D,L-2-aceetamido-3-fenylpropionaat met formule 1 van het formuleblad.The invention relates to a new compound with anti-depressant activity, namely 1-aminoadamantane D, L-2-acetamido-3-phenylpropionate of formula 1 of the formula sheet.
De verbinding 1-aminoadamantaan (ook bekend als amantadine) wordt 5 sedert enkele jaren therapeutisch gebruikt om zijn werkzaamheid tegen in-fluenzavirus type A en tegen de ziekte van Parkinson.The compound 1-aminoadamantane (also known as amantadine) has been used therapeutically for several years for its efficacy against influenza type A virus and Parkinson's disease.
Toepassing van deze stof wordt echter beperkt doordat bij de volledige dosering voor therapeutisch gebruik, namelijk 1*00 mg/dag, ongewenste neveneffecten kunnen optreden, die zo ernstig kunnen zijn, dat de 10 behandeling moet worden afgebroken.(Valleeorsi G. et al., Clin.Ter., 77, 53 - 60, 1976 - Cloarec M. et al., Sem.Hop.Paris, 52, 889, 1976).However, use of this substance is limited by the fact that at the full dosage for therapeutic use, namely 1 * 00 mg / day, undesirable side effects may occur, which may be so severe that treatment must be discontinued (Valleeorsi G. et al. , Clin.Ter., 77, 53-60, 1976 - Cloarec M. et al., Sem.Hop.Paris, 52, 889, 1976).
Nu is verrassenderwijze gevonden, dat het zout van 1-aminoadaman-taan met D,L-aceetamido-3-fenylpropionzuur, de verbinding met formule 1, bij toediening van eenzelfde gewichtsdosis als amantadine, een farmacolo-15 gische werkzaamheid vertoont, die van psycho-stimulerend standpunt vol-’ leidig vergelijkbaar is met die van amantadine, maar in het geheel geen nadelige neveneffecten vertoont, terwijl de verbinding daarentegen wel een duidelijke anti-depressieve werkzaamheid vertoont, die bij amantadine zelf niet aanwezig is.It has now surprisingly been found that the salt of 1-aminoadamane with D, L-acetamido-3-phenylpropionic acid, the compound of formula 1, when administered at the same weight dose as amantadine, exhibits a pharmacological activity, that of psychoactive The stimulating position is completely similar to that of amantadine, but does not show any adverse side effects at all, whereas the compound, on the other hand, shows a marked anti-depressant activity, which is not present with amantadine itself.
20 De verbinding heeft eveneens betrekking op farmaceutische prepara ten, welke als werkzaam bestanddeel de verbinding met formule 1 bevatten en welke geschikt zijn voor de behandeling van involutionele en depressive toestanden van de preseniele leeftijd, alle psychomotorische storingen van hogere leeftijd en eveneens, als hulpmiddelen, voor alle sto-25 ringen van de hersenfunctie. Tenslotte heeft de uitvinding betrekking op een werkwijze om de verbinding met formule 1 te bereiden, door praktisch equimolaire hoeveelheden D ,L-2-aceetamido-3-fenylpropionzuur en 1-araino-adamantaan met elkaar te laten reageren in een oplosmiddel, dat bij voorkeur bestaat uit lage alcoholen, bijvoorbeeld ethanol, methanol of propa-30 nol en uit dat oplosmiddel het zout met formule 1 neer te slaan door toevoegen van een niet-oplosmiddel (diëthylether, aceton, methylethylketon). De reactie kan doelmatig worden uitgevoerd bij het kookpunt van het mengsel.The compound also relates to pharmaceutical preparations which contain as active ingredient the compound of formula 1 and which are suitable for the treatment of involutional and depressive states of presenile age, all psychomotor disorders of advanced age and also, as auxiliaries, for all brain function disorders. Finally, the invention relates to a method of preparing the compound of formula 1 by reacting practically equimolar amounts of D, L-2-acetamido-3-phenylpropionic acid and 1-araino-adamantane in a solvent, which is preferably consists of low alcohols, for example ethanol, methanol or propanol, and that solvent precipitates the salt of formula 1 by adding a non-solvent (diethyl ether, acetone, methyl ethyl ketone). The reaction can conveniently be carried out at the boiling point of the mixture.
Ook kan de reactie worden uitgevoerd tussen een zout (bijvoorbeeld 35 een natriumzout) van D,L-2-aceetamido-3-fenylpropionzuur en het hydrochloride (of an.df>r zuuradditiezout) van 1-aminoadamantaan.The reaction can also be carried out between a salt (for example a sodium salt) of D, L-2-acetamido-3-phenylpropionic acid and the hydrochloride (or other acid addition salt) of 1-aminoadamantane.
In dat geval wordt het gevormde anorganische zout, bijvoorbeeld - 4)1 00 5 1 0 y*.In that case, the inorganic salt formed becomes, for example - 4).
-2- natriumchloride, uit de ethanoloplossing neergeslagen en afgefiltreerd; daarna wordt de verbinding met formule 1 geïsoleerd, bijvoorbeeld op de hierboven genoemde wijze.-2-sodium chloride, precipitated from the ethanol solution and filtered; then the compound of formula 1 is isolated, for example, in the above-mentioned manner.
De werkwijze volgens de uitvinding wordt geïllustreerd door het 5 volgende voorbeeld.The method according to the invention is illustrated by the following example.
Voorbeeld.Example.
In 250 ml watervrije ethanol worden ^1,½ g (0,2 mol) D,L-2-aceet-amido-3-f'enylpropionzuur en 30,2 g (0,2 mol) 1-aminoadamantaan opgelost. Men laat de oplossing 2-3 uur koken onder terugvloeikoeling; na afkoe-10 len wordt UOO ml diëthylether toegevoegd. Het verkregen ne er slag,: wordt afgefiltreerd en gewassen met diëthylether. Men verkrijgt zo 65,88 g kristallijn kleurloos produkt; smeltpunt 207 - 208°C.Dilute 1, ½ g (0.2 mol) D, L-2-acetamido-3-phenylpropionic acid and 30.2 g (0.2 mol) 1-aminoadamantane in 250 ml anhydrous ethanol. The solution is allowed to reflux for 2-3 hours; after cooling, 100 ml of diethyl ether are added. The precipitate obtained is filtered and washed with diethyl ether. 65.88 g of crystalline colorless product are thus obtained; mp 207-208 ° C.
Analyse van % Berekend: C = 70,35; H = 8,1*3; N = 7,81 15 % Gevonden: C = 70,51; H = 8,38; N = 7,ShAnalysis of% Calculated: C = 70.35; H = 8.1 * 3; N = 7.81 15% Found: C = 70.51; H = 8.38; N = 7, Sh
De verbinding is oplosbaar in ethanol, minder oplosbaar in water en niet oplosbaar in aceton, diëthylether en chloroform.The compound is soluble in ethanol, less soluble in water and insoluble in acetone, diethyl ether and chloroform.
De toxicologische en farmacologische eigenschappen van de verbinding met formule 1 (verder aangeduid onder de codenaam MR-708) werden 20 bepaald volgens de hieronder genoemde methoden.The toxicological and pharmacological properties of the compound of formula 1 (further designated under the code name MR-708) were determined by the methods listed below.
Giftigheid.Toxicity.
'Acute giftigheid."Acute toxicity.
Tabel A toont de waarden, verkregen bij muizen en ratten.Table A shows the values obtained in mice and rats.
TABEL A, 25........ MR-708 Amantadine 30TABLE A, 25 ........ MR-708 Amantadine 30
muis rat os 850 700 \ip 365 F * 205 F ^ OS 1020 F X 890 F ^ip 263 F * 223 Fmouse rat os 850 700 \ ip 365 F * 205 F ^ OS 1020 F X 890 F ^ ip 263 F * 223 F
8100510 -3- * * *8100510 -3- * * *
Herhaalde giftigheid.Repeated toxicity.
Alle onderzot.» uitgevoerd door herhaald toedienen van MR-708 toonde geen enkel van giftigheid hij de verschillende parameters van het bloed, de lever en de nierfunctie en evenmin microscopische of macrosco-5 pische veranderingen van de verschillende onderzochte organen.All the fools. ” performed by repeated administration of MR-708 showed no toxicity at all, the various parameters of the blood, liver and renal function, nor microscopic or macroscopic changes of the different organs examined.
Farmacologie.Pharmacology.
Invloed on de bloeddruk.Influence on blood pressure.
MR-708 leidde tot een geringe en voorbijgaande verhoogde bloeddruk bij toediening aan genarcotiseerde honden in een dosis van 4,5 mg/kg of 10 aan ratten, die varen genarcotiseerd door tweezijdige vagotomie in een dosis van 5 mg/kg.MR-708 resulted in mild and transient elevated blood pressure when administered to narcotized dogs at a dose of 4.5 mg / kg or 10 to rats, which are anesthetized by two-sided vagotomy at a dose of 5 mg / kg.
Versterking van het effect, dat vordt veroorzaakt door L-dopa.Amplification of the effect caused by L-dopa.
Bij muizen veroorzaakt voorbehandeling met MR-708 in een intra-peritonale dosis van 70 mg/kg 90 minuten v66r intraperitonaal toedienen 15 van L-dopa in een dosis van 500 mg/kg tot een duidelijke psychosomatische opwinding, die reeds begint te verschijnen voör de tiende minuut na toediening van L-dopa en op de 25ste minuut, vanneer L-dopa vordt toegediend in een dosis van 1000 mg/kg. Ook het aantal aanvallen is groter; MR-708 versterkt dus het effect van L-dopa doordat bij een geringere dosis reeds 20 dezelfde symptonen verschijnen, terwijl die symptonen ook eerder verschijnen.In mice, pretreatment with MR-708 at an intraperitoneal dose of 70 mg / kg causes 90 minutes prior to intraperitoneal administration of L-dopa at a dose of 500 mg / kg to a marked psychosomatic excitement that begins to appear before 10th minute after L-dopa administration and 25th minute, L-dopa is administered at a dose of 1000 mg / kg. The number of attacks is also greater; MR-708 thus enhances the effect of L-dopa because 20 of the same symptoms already appear at a smaller dose, while those symptoms also appear earlier.
Antagonisme tegen de giftige werking van nicotine.Antagonism against the toxic effect of nicotine.
Bij intraperitonale toediening van 25 mg/kg MR-708 aan ratten, blijken die ratten te worden beschermd tegen de giftige werking van nieo-25 tine.Intraperitoneal administration of 25 mg / kg MR-708 to rats has been shown to protect those rats from the toxic action of nieo-25 tine.
Antagonisme tegen de giftige werking van amfetamine.Antagonism against the toxic effect of amphetamine.
Een intraperitonale dosis van 25 mg/kg MR-708 beschermt tegen de giftige werking van amfetamine, doordat de LD ^-vaarde significant wordt veranderd.An intraperitoneal dose of 25 mg / kg MR-708 protects against the toxic action of amphetamine by significantly altering the LD 1 value.
30 Antagonisme tegen de giftige werking van epinefrine.30 Antagonism against the toxic effect of epinephrine.
Een intraperitonale dosis van 25 mg/kg MR-708 beschermt ratten tegen de giftige werking van epinefrine.An intraperitoneal dose of 25 mg / kg MR-708 protects rats from the toxic action of epinephrine.
Antagonisme tegen ethanol.Antagonism against ethanol.
Een enkele orale dosis van 150 mg/kg MR-708 vermindert bij vrouve-35 lijke Wistar-ratten de slaapduur, veroorzaakt door vrije ethanol, met ongeveer 45 %*A single oral dose of 150 mg / kg MR-708 reduces the duration of sleep caused by free ethanol in female Wistar rats by approximately 45% *
Antagonisme tegen chloraalhydraat.Antagonism against chloral hydrate.
Een enkele orale dosis van 150 mg/kg Mr-708 toegediend aan mannelijke Wistar-ratten, vermindert de slaapduur, veroorzaakt door een intra- 8100510 -U-.A single oral dose of 150 mg / kg Mr-708 administered to male Wistar rats reduces the duration of sleep caused by an intra-8100510 -U-.
peritonale dosis van 300 mg/kg chloraalhydraat, met ongeveer 26 %.peritoneal dose of 300 mg / kg of chloral hydrate, by approximately 26%.
Blokkering van de ingewandsbewegingen.Blockage of the viscera.
Een intraperitonale dosis van 25 mg/kg MR-708 Bij ratten vertoont Bij de houtskoolingestieproef een duidelijke werkzaamheid op de Blokke-5 ring van de ingewandsbeweging, die zeer significant is in vergelijking met de Blanco groep.An intraperitoneal dose of 25 mg / kg MR-708 In rats In the charcoal test, it shows a clear activity on the blocking of the visceral movement, which is very significant compared to the Blanco group.
Mydriatische werkzaamheid.Mydriatic efficacy.
Een intraperitonale dosis van 25 mg/kg MR-708 Bij ratten vertoont Bij herhaald onderzoek respectievelijk 30, 60, 120 en 2^0 minuten na toe-10 diening in vergelijking met de controledieren milde veranderingen in de diameter van de pupil, welke echter duidelijk kleiner zijn dan die, welke worden veroorzaakt door atropine.An intraperitoneal dose of 25 mg / kg MR-708 In rats In repeated studies, 30, 60, 120 and 20 minutes after administration, compared to the control animals, exhibits mild changes in the diameter of the pupil, which, however, are evident smaller than those caused by atropine.
Speciale farmacologie.Special pharmacology.
Antagonisme tegen de hypothermiante werkzaamheid van reserpine.Antagonism against the hypothermic effect of reserpine.
15 Een voorbehandeling met MR-708 Bij muizen in een orale dosis van 25 mg/kg antagoniseert zeer significant de hypothermiante werking, veroorzaakt door intraperitonale toediening van reserpine in een dosis van 25 mg/kg.Pretreatment with MR-708 In mice at an oral dose of 25 mg / kg very significantly antagonizes the hypothermic effect caused by intraperitoneal administration of reserpine at a dose of 25 mg / kg.
Alle veranderingen zijn nog duidelijker in ongeveer het derde uur 20 en ze Blijven significant tot en met dat derde uur.All changes are even more apparent in about the third hour and they remain significant through that third hour.
Antagonisme tegen de zweervormende werkzaamheid van reserpine.Antagonism against the ulcerative activity of reserpine.
Een orale dosis van 25 mg/kg MR-708, aan muizen toegediend 1 uur v66r intraperitonale toediening van 2,5 mg/kg reserpine antagoniseert de zweervormende werking van reserpine. Post mortem-onderzoek van de proef-.25 dieren, gedood 22 uur na de Behandeling, toonde Bij 99 % van de controledieren relevante maagbloedingen en ingewandszweren, die gepaard gingen met een rijkelijke aanwezigheid van Bloed in de darminhoud. In de groep, welke MR-708 had ontvangen, vertoonde slechts 10 % van de proefdieren zweervorming in de ingewanden en dan nog in nauwelijks relevante mate.An oral dose of 25 mg / kg MR-708 administered to mice 1 hour before intraperitoneal administration of 2.5 mg / kg reserpine antagonizes the ulcer-forming activity of reserpine. Post-mortem examination of the test .25 animals, killed 22 hours after treatment, showed relevant gastric haemorrhage and intestinal ulceration associated with a profuse presence of blood in the gut contents in 99% of control animals. In the group that had received MR-708, only 10% of the test animals had intestinal ulceration, and then still hardly relevant.
30 Beschermende werking tegen maagzweren, onder invloed van spanningen^_30 Protective action against stomach ulcers, under the influence of stress ^ _
Toediening van 75 mg/kg MR-708 geeft een Beschermende werking tegen maagzweren onder invloed van spanningen in een zeer significante mate, vergeleken met de controledieren.Administration of 75 mg / kg MR-708 has a very significant protective effect against gastric ulcers under stress, compared to the control animals.
Invloed op katatonische syndromen Bij ratten, veroorzaakt door haloperidol._____Influence on catatonic syndromes In rats caused by haloperidol ._____
Een intraperitonale dosis van 6,25 - 25 mg/kg MR-708 Bij ratten, •.werkt significant de passieve aanvaarding tegen van een gewoonte, die teweeg is gebracht door intraperitonale toediening van 7,5 mg/kg halo- 35 8100510 -5- peridol (proef van Simon Boissiet, 1969).An intraperitoneal dose of 6.25 - 25 mg / kg MR-708 In rats, • significantly counteracts the passive acceptance of a habit induced by intraperitoneal administration of 7.5 mg / kg halo 35 8100510-5 - peridol (test by Simon Boissite, 1969).
Invloed on de oriëntatierespons na herhaalde elektrische schokken.Influence on the orientation response after repeated electric shock.
Intraperitonale toediening van doses van 3,125 en 6,25 mg/kg MR-708 60 minuten v6or de elektrische schok "blijkt de integriteit van 5 de hersenstructuren te handhaven ondanks de schadelijke werking van herhaalde elektrische schokken (proef van Herald, i960).Intraperitoneal doses of 3.125 and 6.25 mg / kg MR-708 60 minutes prior to electric shock "have been shown to maintain the integrity of brain structures despite the deleterious effects of repeated electric shocks (Herald's trial, 1960).
Fannacokinetica.Fanokinetics.
De "bepaling van de plasmaconcentraties van 1 -aminoadamantaan bij ratten na orale toediening van MR-708 bij muizen leidt tot de volgende 10 opmerkingen:The determination of the plasma concentrations of 1-aminoadamantane in rats after oral administration of MR-708 in mice leads to the following 10 comments:
De kinetica van de W-deacetylatie maakt progressief vrijmaken mogelijk van fenylalanine. Dit proces vertraagt het levermetabolisme en versterkt de specifieke werking omdat geleidelijk meer nieuw fenylala-nine vrijkomt, dat daarna door de barrière tussen bloed en hersenen kan 15 dringen. Ha toedienen van 190 mg/kg MR-708 langs orale weg aan muizen, wijzen de plasmaspiegels van 1-aminoadamantaan in vergelijking met die, verkregen na toediening van een equimolaire dosis 1-aminoadamantaahhydro-chloride (100 mg/kg) (beide doses komen overeen met 0,5^ mmol/kg) op een betere biologische beschikbaarheid van MR-708; uit de verhouding van de 20 oppervlakken onder de krommen voor de plasmaspiegels (AUC) blijkt, dat er 29,72 % verschil is in de biologische beschikbaarheid, waarbij MR-708 het gunstigst is.The kinetics of W-deacetylation allow progressive release of phenylalanine. This process slows down liver metabolism and enhances specific activity as more new phenylalanine is released gradually, which can subsequently penetrate the barrier between blood and brain. Ha administration of 190 mg / kg MR-708 orally to mice indicates plasma levels of 1-aminoadamantane compared to those obtained after administration of an equimolar dose of 1-aminoadamantaahhydrochloride (100 mg / kg) (both doses corresponds to 0.5 ^ mmol / kg) on better bioavailability of MR-708; The ratio of the 20 areas under the plasma levels (AUC) curves shows that there is a 29.72% difference in bioavailability with MR-708 being the most favorable.
Verder blijkt de dispersie van de resultaten geringer te zijn bij toediening van MR-708 dan bij toediening van 1-amino-adamantaanhydrochlo-25 ride.Furthermore, the dispersion of the results appears to be lower when administering MR-708 than when administering 1-amino-adamantane hydrochloride.
Wanneer de standaarddeviatie wordt uitgedrukt als percentage van het gemiddelde, blijkt bij 1-aminoadamantaanhydrochloride een variatie van ^2,7 % op te treden en bij MR-708 slechts 2k,6 %.When the standard deviation is expressed as a percentage of the mean, 1-aminoadamantane hydrochloride shows a variation of ^ 2.7% and MR-708 only 2k, 6%.
81005108100510
Claims (3)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT20075/80A IT1147325B (en) | 1980-02-21 | 1980-02-21 | COMPOUND WITH PSYCHO-STIMULATING AND ANTIDEPRESSANT ACTIVITY, PROCESS FOR ITS PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS |
IT2007580 | 1980-02-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
NL8100510A true NL8100510A (en) | 1981-09-16 |
Family
ID=11163600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL8100510A NL8100510A (en) | 1980-02-21 | 1981-02-03 | 1-AMINOADAMANTS D, L-2-ACETAMIDO-3-PHENYL PROPIONATE. |
Country Status (10)
Country | Link |
---|---|
JP (1) | JPS56128745A (en) |
BE (1) | BE887351A (en) |
CA (1) | CA1144162A (en) |
CH (1) | CH648290A5 (en) |
DE (1) | DE3008335C2 (en) |
FR (1) | FR2476643B1 (en) |
GB (1) | GB2070004B (en) |
IT (1) | IT1147325B (en) |
NL (1) | NL8100510A (en) |
ZA (1) | ZA81523B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5950269U (en) * | 1982-09-28 | 1984-04-03 | ダイワ精工株式会社 | Level winder with double bearing type reel for fishing |
JPS61260824A (en) * | 1985-05-15 | 1986-11-19 | 株式会社 オリムピツク | Production of line guide in parallel winding mechanism of double bearing reel |
-
1980
- 1980-02-21 IT IT20075/80A patent/IT1147325B/en active
- 1980-03-05 DE DE3008335A patent/DE3008335C2/en not_active Expired
-
1981
- 1981-01-21 CH CH398/81A patent/CH648290A5/en not_active IP Right Cessation
- 1981-01-26 CA CA000369264A patent/CA1144162A/en not_active Expired
- 1981-01-26 ZA ZA00810523A patent/ZA81523B/en unknown
- 1981-01-27 JP JP1145881A patent/JPS56128745A/en active Granted
- 1981-01-30 GB GB8102912A patent/GB2070004B/en not_active Expired
- 1981-02-03 BE BE2/58995A patent/BE887351A/en not_active IP Right Cessation
- 1981-02-03 NL NL8100510A patent/NL8100510A/en not_active Application Discontinuation
- 1981-02-18 FR FR8103203A patent/FR2476643B1/fr not_active Expired
Also Published As
Publication number | Publication date |
---|---|
IT8020075A0 (en) | 1980-02-21 |
GB2070004B (en) | 1983-10-26 |
DE3008335C2 (en) | 1982-03-04 |
CH648290A5 (en) | 1985-03-15 |
DE3008335A1 (en) | 1981-08-27 |
IT1147325B (en) | 1986-11-19 |
GB2070004A (en) | 1981-09-03 |
JPS5747178B2 (en) | 1982-10-07 |
ZA81523B (en) | 1982-02-24 |
FR2476643B1 (en) | 1983-05-13 |
BE887351A (en) | 1981-06-01 |
CA1144162A (en) | 1983-04-05 |
FR2476643A1 (en) | 1981-08-28 |
JPS56128745A (en) | 1981-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005228685B2 (en) | Hydrazide-containing CFTR inhibitor compounds and uses thereof | |
CZ177596A3 (en) | 2,4-disulfonylphenylbutylnitrone, salts thereof and the use of the salts as medicaments | |
CS208660B2 (en) | Method of making the n-/2-phenyl-2-hydroxyethyl/-1,1-dimethyl-3-phenylpropylamin derivatives | |
US20090326037A1 (en) | Medicinal Agent For Treating Viral Infections | |
JPS6339567B2 (en) | ||
WO1995015155A1 (en) | Taste masked composition containing a drug/polymer complex | |
CN111635315B (en) | Antipyretic analgesic medicine and preparation method and application thereof | |
WO2005123651A1 (en) | L-2-(α-HYDROXYPENTYL)BENZOATES, THE PREPARATION AND THE USE THEREOF | |
US6677381B1 (en) | Guaifenesin tannate | |
NL8100510A (en) | 1-AMINOADAMANTS D, L-2-ACETAMIDO-3-PHENYL PROPIONATE. | |
US4144328A (en) | N,N,N-Trimethyl derivatives of polyene amphoteric antibiotics, process of producing same and pharmaceutical composition | |
EP1037888A1 (en) | ($i(E))-3- 1-$i(N)-BUTYL- 5- 2-(2-CARBOXYPHENYL)METHOXY- 4-CHLOROPHENYL]-1$i(H)- PYRAZOL-4-YL]-2- (5- METHOXY-2,3- DIHYDROBENZOFURAN-6-YL)METHYL]- PROP-2-ENOIC ACID MONOARGININYL SALT | |
US4191780A (en) | Bromhexine derivatives and process for making same | |
US20160038505A1 (en) | Methods and compositions for treating impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake | |
US6034126A (en) | Method for treating glycol poisoning | |
JP2548223B2 (en) | Kidney disease treatment | |
JPS60208914A (en) | Preventive and remedy for hepatic disorder | |
US6172119B1 (en) | Method of treating acute renal failure | |
DE2462814C2 (en) | ||
FI68812C (en) | EFFECTIVE EFFECTIVENESS OF THERAPEUTIC EFFECTIVE 1- OCH D, 1-GLAUSINLACTATSALTER | |
DE2408372A1 (en) | PHARMACEUTICAL PREPARATIONS ON THE BASIS OF HIPPURIC ACID DERIVATIVES | |
JPH04208223A (en) | Therapeutic agent for hepatopathy | |
CA1301776C (en) | Compound of choline, a process for its preparation and therapeutic composition containing it | |
RU2061472C1 (en) | Composition showing antimicrobial effect | |
DE2302593C3 (en) | Salts of Silymarins-I with Monoaminopoiyhydroxyalkoholen and process for their preparation and medicinal products containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1A | A request for search or an international-type search has been filed | ||
BB | A search report has been drawn up | ||
BC | A request for examination has been filed | ||
A85 | Still pending on 85-01-01 | ||
BV | The patent application has lapsed |